At a Glance
- CD34+ cell therapy platform yielding a 4-product clinical pipeline, 2 with “breakthrough” designation and 1 targeting lung repair in COVID-19 survivors
- Proprietary field-leading technology in multi-billion-dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12-18 months based on milestones across the pipeline (timing subject to COVID-19 pandemic influence)
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
- Strong balance sheet; ~$40.3 million in cash & cash equivalents (9/30/2020) with no debt and cash runway projected to fund operations through 2021
Maximum 30 minute delay for quote.